Page 33 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Benzodiazepine use and retention in OAT

Methodology and Location Retrospective chart analysis of patients who received at least one buprenorphine prescription in Boston, USA. Retrospective cohort analysis linking five collections of data sets from Massachusetts, USA of buprenorphine users. Observational cohort study in Ireland Retrospective chart review of postpartum women with OUD treated with buprenorphine at Women’s Mental Health Program in Arkansas, USA

Psychiatric Comorbidity Depression 85% Anxiety 70% Other mood disorder 61% Depression 27% Anxiety 22% Bipolar/psychosis 7% Antidepressants 48% Antipsychotics 24% DSM Axis 1 disorder 84% Depression 57% PTSD 48% ND ND

Polysubstance use Other substance use disorder 60% ND ND Nicotine use 80% Other substance use disorder 77% Cannabis 29% Cocaine 34% ND

Behavioral Health Clinic Multiple addiction services Women’s Mental Health Program at university hospital Not-for-profit, treatment program Multiple

Setting Primary care and specialist community-based opioid

MOUD dose (±SD) ND Buprenorphine 0>16 mg/day Methadone range<60 – >120 mg/day Buprenorphine 17.8 (6.1) mg/day ND Buprenorphine dose range 0 to 24+mg/day Abbreviations: BZT: Benzodiazepine; DSM: Diagnostic and Statistical Manual of Mental Disorders; F: Female; M: Male; MMT; Methadone maintenance treatment; ND: Not determined;

Sex (%) 62% M: 38% F 38% F 68% M 100% F 63% M: 37% F 61% M 37% F

Age (±SD) 38 (10) 38 (11) 34.4 28.1 (4.4) 37 (11) 18 – 65+ OAT: Opioid agonist treatment; OUD: Opioid use disorder; PTSD: Post-traumatic stress disorder; Ss: Subjects.

Number of Subjects 321 63345 2035 64 2968 4898

Table 3. (Continued) Study Montalvo et al. 51 Park et al. 46 Durand et al. 41 Ray-Griffith et al. 38 Morford et al. 39 Hallowell et al. 44

Volume 8 Issue 3 (2025) 27 doi: 10.36922/itps.5151